A double-blind, randomized, placebo-controlled clinical trial of S-Adenosyl-L-Methionine (SAMe) versus escitalopram in major depressive disorder

Journal of Clinical Psychiatry

Volumn 75, Issue 4, 2014, Pages 370-376

  Mischoulon, David ^a   Price, Lawrence H ^b   Carpenter, Linda L ^b   Tyrka, Audrey R ^b   Papakostas, George I ^a   Baer, Lee ^a   Dording, Christina M ^a   Clam, Alisabet J ^a   Durham, Kelley ^a   Walker, Rosemary ^a   Ludington, Elizabeth ^c   Fava, Maurizio ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROWN UNIVERSITY   (United States)

^c and Training)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; PLACEBO; S ADENOSYLMETHIONINE;

ADULT; AGED; ANORGASMIA; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV; FAINTNESS; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON DEPRESSION RATING SCALE 17; HAMILTON SCALE; HOT FLUSH; HUMAN; INSOMNIA; LEG PAIN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEXUAL DYSFUNCTION; STOMACH DISCOMFORT; SYSTEMATIC ASSESSMENT FOR TREATMENT OF EMERGENT EVENT SPECIFIC INQUIRY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; S-ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899735292     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.13m08591     Document Type: Article

References (29)

1. Spiflmann M, Fava M. S adenosyl methionine (ademethionine) in psychiatric disorders. N5 Drugs. 1996;6(6):416-425.
2. Baldessarini RJ. Neuropharmacology of S adenosyl L methionine. Am JMed. 1987;83(5A):95-103.
3. Papakostas GI, Alpert JE, Fava M. S adenosyl methionine in depression: A comprehensive review of the literature. Curr Psychiatry Rep. 2003;5(6): 460-466.
4. Papakostas GI. Evidence for S adenosyl L methionine (SAM e) for the treatment of major depressive disorder. I Clin Psychiatry. 2009;70(suppl 5): 18-22.
5. Papakostas GI, Mischoulon D, Shyu I, et al. S adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: A double blind, randomized clinical trial. Am J Psychiatry. 2010;167(8):942-948.
6. Burke WJ, Gergel I, Bose A. Fixed dose trial of the single isomer SSRI escitalopram in depressed outpatients. I Clin Psychiatry. 2002;63(4):331-336.
7. Quitkin FM, Rabkin JG, Stewart JW, et al. Study duration in antidepressant research: Advantages of a 12 week trial. JPsychiatrRes. 1986;20(3):211-216.
8. World Health Organization. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ. 2001;79(4):373-374.
9. First BM, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM IV Axis I Disorders Patient Edition (SCID lIP). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1995.
10. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS): Psychometric properties. Psychol Med. 1996;26(3): 477-486.
11. Hamilton M. A rating scale for depression. I Neurol Neurosurg Psychiatry. 1960;23(1):56
12. Hamilton M. Development of a rating scale for primary depressive illness. BrJSoc Clin Psychol. 1967;6(4):278-296.
13. Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45(8):742-747.
14. Guy W ECDEU Assessment Manualfor Psychopharmacology, Revised. Department of Health, Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976.
15. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire (Q LES Q): A new measure. Psychopharmacol Bull. 1993;29(2):321-326.
16. Sherbourne CD, Wells KB, Hays lID, et al. Subthreshold depression and depressive disorder: Clinical characteristics of general medical and mental health specialty outpatients. Am I Psychiatry. 1994;151 (12): 1777-1784.
17. Wells KB, Stewart A, Hays RD, et al. The functioning and well being of depressed patients: Results from the Medical Outcomes Study. JAMA. 1989;262(7):914-919.
18. Fava M, Rosenbaum JF, McCarthy M, et al. Anger attacks in depressed outpatients and their response to fluoxetine. Psychopharmacol Bull. 1991;27(3):275-279.
19. Rabkin JG, Markowitz JS, Ocepek Welikson K, et al. General versus systematic inquiry about emergent clinical events with SAFTEE: Implications for clinical research. I Clin Psychopharmacol. 1992;12(1):3
20. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; lOSS.
21. Insel TR, Wang PS. The STAR D trial: Revealing the need for better treatments. Psychiatr Serv. 2009;60( 11): 1466-1467.
22. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? a meta regression of double blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19(1):34
23. Lovieno N, Papakostas GI. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: A meta analysis. I Clin Psychiatry. 2012;73(10):1300-1306.
24. Freeman M Mischoulon D, Tedeschini E, et al. Complementary and alternative medicine for major depressive disorder: A meta analysis of patient characteristics, placebo response rates, and treatment outcomes relative to standard antidepressants. I Clin Psychiatry. 2010;71(6):682-688.
25. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John?s wort) in major depressive disorder: A randomized controlled trial. JAMA. 2002;287(14):1807-1814.
26. Chen JA, Papakostas GI, Youn SJ, et al. Association between patient beliefs regarding assigned treatment and clinical response: Reanalysis of data from the Hypericum Depression Trial Study Group. I Clin Psychiatry. 2011;72(12): 1669-1676.
27. Golden RN, NemeroffCB, McSorley P, et al. Efficacy and tolerability of controlled release and immediate release paroxetine in the treatment of depression. I Clin Psychiatry. 2002;63(7):577-584.
28. Posternak MA, Zimmerman M. Short term spontaneous improvement rates in depressed outpatients. I Nerv Ment Dis. 2000;188(12) :799-804.
29. Alpert JE, Papakostas G, Mischoulon D, et al. S adenosyl L methionine (SAMe) as an adjunct for resistant major depressive disorder: An open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. I Clin Psychopharmacol. 2004;24(6):661-664.